ReviewBMC nephrology2025
Unclassified renal cell carcinoma with multi-organ metastasis treated with surgery and targeted therapy combination: a case report and literature review.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We present a rare case of unclassified renal cell carcinoma (RCC) in a 66-year-old woman, exhibiting multi-organ invasion. The patient was asymptomatic until a health exam revealed a left renal mass. CT scans showed an irregular, 6.8 × 8.9 cm mass involving the renal sinus, with possible pancreatic infiltration and retroperitoneal lymph node metastasis. Intraoperative findings necessitated multi-organ resection, including the left kidney, spleen, and portions of the pancreas. Histopathology confirmed unclassified RCC, positive for CA-9, CD10, Vim, and negative for P504S, CD99, Desmin. Post-surgery, the patient received cabozantinib and nivolumab, and remains progression-free at 22 months of follow-up. This case analyzed the diagnosis and treatment of aggressive unclassified RCC, and showed good efficacy after extensive surgical resection and combined treatment with cabozantinib and nivolumab, which may help further study of unclassified RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.